Our operating basic principle is to produce reliable and efficient top quality products, therefore every JSC Olainfarm product is thoroughly tested and traced in different stages of its life cycle. Our Pharmacovigilance Group ensures the monitoring of safety use of medicinal products for which we are marketing authorization holders on the market and also for medicinal products under ongoing clinical studies. Also the Pharmacovigilance Group shall carry out the following:
- Identify new potential risks that may affect the quality, safety and efficacy of the medicinal product,
- Evaluates the medicinal products benefit risk ratio,
- Provide up-to-date information on the use of medicines to doctors, pharmacists, patients, JSC Olainfarm’s Representative offices and partners.
JSC Olainfarm receives safety information from physicians, pharmacists, other healthcare professionals, our Representative offices abroad, partners and patients. We will carefully evaluate it and, if necessary, provide the information to the EU safety data base Eudravigilance under supervision of European Medicines Agency. In case of necessity the information might be provided to other pharmacovigilance related Regulatory Authorities and our Representative offices abroad.
Patients, their relatives, doctors, pharmacists, other health care professionals, any other interested persons, if necessary, can and are welcomed to report on JSC Olainfarm drug side effects to our headquarters via e-mail firstname.lastname@example.org or by phones: working hours: (+371) 67103724 or 24/7 mobile phone (+371) 26137761or as to the our Representative Offices abroad/ Subsidiaries at your country
(//lv.olainfarm.com/company/olainfarm-worldwide/). In case the information will be submitted to the headquarters, you will receive the information regarding recording and storing of your personal data.
Dr. Uldis Armanis; Mg.sc.sal.
EU Qualified Person Responsible for Pharmacovigilance at JSC Olainfarm.